@CUCancerCenter

Official X page of the University of Colorado Anschutz Cancer Center - Colorado's only @theNCI-designated comprehensive cancer center.

 Aurora, Colo.
coloradocancercenter.org
Joined October 2008
  • Tweets25.3K
  • Following1.4K
  • Followers9.9K
18.2KMedia
CU Anschutz Cancer Center's Theresa Medina, MD, provides insight into what impact the Keytruda-intismeran combination may have for high-risk melanoma patients ⬇️ uchealth.org/today/mrna-canc…

Clinical trials: New mRNA cancer vaccine plus Keytruda sharply improves melanoma survival

A personalized melanoma vaccine developed by Moderna and Merck, used with Keytruda, greatly reduced melanoma recurrence risk in trials.

uchealth.org
139
Congratulations to Wells Messersmith, MD, the new director of the CU Anschutz Cancer Center. See the full statement: bit.ly/4yiL1oE
"New Director of the CU Anschutz Cancer Center" in smaller text, broken up by a line of CU gold dots with larger text "Wells Messersmith, MD". There is a cutout photo of Messersmith to the right, with a CU gold dotted background behind him. The CU Anschutz Cancer Center logo is in the bottom left.

ALT "New Director of the CU Anschutz Cancer Center" in smaller text, broken up by a line of CU gold dots with larger text "Wells Messersmith, MD". There is a cutout photo of Messersmith to the right, with a CU gold dotted background behind him. The CU Anschutz Cancer Center logo is in the bottom left.

2
6
2
32
3,075
The @AACR's 2026 Cancer Progress Report highlights the latest progress in the fight against cancer. CU Anschutz Cancer Center leader James DeGregori, PhD, shares his thoughts as a member of the report's steering committee: news.cuanschutz.edu/cancer-c…
A photo of James DeGregori, PhD, to the left. Then a photo of the cover of the AACR Cancer Progress Report 2026 in the middle. To the bottom right, is a photo of cancer ribbons. The background is CU gold on the left and then white to the right.

ALT A photo of James DeGregori, PhD, to the left. Then a photo of the cover of the AACR Cancer Progress Report 2026 in the middle. To the bottom right, is a photo of cancer ribbons. The background is CU gold on the left and then white to the right.

1
2
252
CU Anschutz Cancer Center retweeted
CU Anschutz Lymphoma Program@CULymphoma
Sep 18
Check out the @VJHemOnc #podcast for an interview with our @CULymphoma lead Dr. @mana1981 on use of BTK inhibitors in NHL. #lymsm @CUCancerCenter @CUDeptMedicine @CUAnschutz
VJHemOnc
@VJHemOnc
Sep 16
Want practical advice on using BTK inhibitors in clinical practice across #NonHodgkinLymphoma subtypes? 🩺 Make sure to check out our podcast episode with Manali Kamdar (@mana1981) to learn about: 🩸 Selecting patients for BTKi therapy 🩸 Adverse event counseling & management 🩸 Response monitoring & treatment at progression Listen NOW: 👉 ow.ly/IU0Z50ZMx5G #Lymphoma #LYMsm #MantleCellLymphoma #DLBCL #HemOnc @CULymphoma @CUMedicalSchool
1
2
4
465
📸 from Cancer League Colorado's Over the Edge this morning! James DeGregori, PhD, interim director, and Mercedes Rincon, PhD, a cancer center member, rappelled down the Kimpton Claret Hotel for Colorado-based cancer research. 💛
James DeGregori, PhD, interim director of the CU Anschutz Cancer Center, and Mercedes Rincon, PhD, with one of the attendees.

ALT James DeGregori, PhD, interim director of the CU Anschutz Cancer Center, and Mercedes Rincon, PhD, with one of the attendees.

James DeGregori, PhD, interim director of the CU Anschutz Cancer Center, and Mercedes Rincon, PhD, about to rappel.

ALT James DeGregori, PhD, interim director of the CU Anschutz Cancer Center, and Mercedes Rincon, PhD, about to rappel.

James DeGregori, PhD, interim director of the CU Anschutz Cancer Center, and Mercedes Rincon, PhD

ALT James DeGregori, PhD, interim director of the CU Anschutz Cancer Center, and Mercedes Rincon, PhD

1
1
287
CU Anschutz Cancer Center's Laura Graham, MD, and Enrique Soto (@EnriqueSoto8), MD, PhD, share their thoughts on hormone therapy as a treatment for breast cancer and prostate cancer ⬇️ news.cuanschutz.edu/cancer-c…

What to Know About Hormone Therapy

Primarily used to treat breast cancer and prostate cancer hormone therapy is an effective treatment method.

news.cuanschutz.edu
1
1
281
CU Anschutz Cancer Center's Maria Amaya, MD, PhD, shares why last Friday's Mentored Member Collaborative Forum is important for mentored members like herself.
212
The CU Anschutz Cancer Center is hosting the second annual Rising Star Over the Rockies Conference! With this event, researchers discuss innovative research, early detection, multidisciplinary care, and education.
A group photo.

ALT A group photo.

James DeGregori, PhD, speaking.

ALT James DeGregori, PhD, speaking.

Discussion between attendees.

ALT Discussion between attendees.

Attendees at Tstreet Kitchen.

ALT Attendees at Tstreet Kitchen.

2
242
.@CUAnschutz researchers have identified a biological pathway that may contribute to muscle and bone loss in colorectal cancer, providing new insight into the mechanisms behind cancer-related wasting and a potential target for future study: bit.ly/4zWVIPj
A photo of a person stretching out their left arm with assistance from another person. The background is white on top, CU gold on the bottom.

ALT A photo of a person stretching out their left arm with assistance from another person. The background is white on top, CU gold on the bottom.

1
4
203
Towards the end of August, the Rady Esophageal and Gastric Center of Excellence hosted its second annual Research Day along with a two-day immersive grant-writing workshop! Thank you to everyone who came out for these events and made them possible.
A group photo of attendees at the Research Day.

ALT A group photo of attendees at the Research Day.

A presentation at the Research Day.

ALT A presentation at the Research Day.

Group discussion during Research Day.

ALT Group discussion during Research Day.

Two presenters at the Research Day.

ALT Two presenters at the Research Day.

1
255
Through the CU-GENES study, Colorado adults of Jewish ancestry can receive free at-home genetic testing. For Michele Frishman, this program helped her learn she was positive for a BRCA1 mutation, a mutation that increases breast and ovarian cancer risk: bit.ly/4gzoaiu
Michele Frishman.

ALT Michele Frishman.

1
2
264
A novel combination therapy with first-in-human roots at @CUAnschutz delivered effective and durable responses in patients with advanced, muscle-invasive bladder cancer, according to a new study in the New England Journal of Medicine (@NEJM): bit.ly/4gy26on
A photo of a patient talking to a person doing intake. There is a photo of a diagram of a bladder overlapping the bottom right of the photo of the patient. The background is CU off white. There is a grid behind the main image of the patient.

ALT A photo of a patient talking to a person doing intake. There is a photo of a diagram of a bladder overlapping the bottom right of the photo of the patient. The background is CU off white. There is a grid behind the main image of the patient.

2
5
348
#ProstateCancerAwarenessMonth: Two CU Anschutz Cancer Center clinical trials may offer new hope for patients with advanced prostate cancer, where the disease has spread beyond the prostate gland and is no longer responding to hormone therapies: bit.ly/4gOUr3Z
Two cancer cells, one is gold and one is silver.

ALT Two cancer cells, one is gold and one is silver.

2
204
CU Anschutz Cancer Center retweeted
CU Anschutz Neurosurgery
@CUNSGY
Sep 2
Meet Corinna Fukushima, MD, a fellowship-trained neuro oncologist & the newest addition to our growing #BrainTumor team @CUAnschutz: tr.ee/ukr6se @CUCancerCenter @CUMedicalSchool #BrainCancer #Cancer
1
1
591
In a new study, Ajay Major (@majorajay), MD, MBA, and Vincenzo Pizzuti, MD, MS, have tracked a group of blood cancer patients using multiple surveys over the course of two years to see how CAR T-cell therapy impacts their health-related quality of life: bit.ly/3UzIYxF
Vincenzo Pizzuti, MD, MS (left), and Ajay Major, MD, MBA, in the Research Quad at CU Anschutz.

ALT Vincenzo Pizzuti, MD, MS (left), and Ajay Major, MD, MBA, in the Research Quad at CU Anschutz.

4
1
10
970
CU Anschutz Cancer Center member and pediatric oncologist Vanessa Ann Fabrizio, MD, MS, breaks down how leukemia in children is different from adult cases. Learn more: medschool.cuanschutz.edu/col… #ChildhoodCancerAwarenessMonth #BloodCancerAwarenessMonth
3
204
On @9NEWS, CU Anschutz Cancer Center leader and principal investigator for the treatment, Wells Messersmith, MD, shares his thoughts on the @FDA approving daraxonrasib and how it works against pancreatic cancer: 9news.com/video/news/health/…

Daraxonrasib approved by FDA: Pancreatic cancer drug shown to improve survival

FDA announced approval of daraxonrasib, a new targeted treatment for pancreatic cancer. CU Anschutz physician Dr. Wells Messersmith served as principal investigator.

9news.com
2
6
386
CU Anschutz Cancer Center researchers are making progress on finding better treatments for mucosal melanomas. A recent phase I clinical trial showed early promise for overcoming immunotherapy resistance in rare melanomas. Learn more: bit.ly/4wMpSSh

Trial Shows Early Promise for Overcoming Immunotherapy Resistance in Rare Melanomas

Martin McCarter and Kasey Couts found that decitabine is effective in reversing the suppression of innate immune pathways in rare melanomas.

news.cuanschutz.edu
1
2
297
The U.S. Food and Drug Administration today approved a new treatment option for patients with advanced pancreatic cancer. Read more about the breakthrough drug from Chris Lieu, MD, associate director of clinical research: bit.ly/4efMpkJ

FDA Approves Breakthrough Pancreatic Cancer Drug – An Oncologist Explains How Daraxonrasib Nearly...

Breakthrough drug nearly doubles survival with advanced pancreatic cancer – an oncologist explains how daraxonrasib overcame an ‘undruggable’ disease

news.cuanschutz.edu
2
189
Immunotherapy, over the last couple of years, promises results for cancer patients for whom other types of treatment have proven ineffective. CU Anschutz Cancer Center leaders explain how it works ⬇️ news.cuanschutz.edu/cancer-c…

What is Immunotherapy? 

Doctors have learned how to harness the immune system to seek out and destroy cancer cells in a targeted fashion that does not destroy healthy cells.

news.cuanschutz.edu
1
3
175
Load more